However, based on recent reports on the effectiveness of SGLT2 inhibitors in the treatment of heart failure and renal failure without diabetes, we believe it is time to discuss the efficacy of these agents in ascites patients without diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.